Weekly treatment aims to protect hemophilia Patients' joints
NCT ID NCT06752850
Summary
This study is checking if a weekly preventative treatment called efanesoctocog alfa can improve joint health in people with moderate or severe Hemophilia A. It will follow about 37 patients in Europe for 12 months, using ultrasound and MRI scans to see if the treatment reduces joint swelling and prevents bleeding episodes. The goal is to see if this weekly regimen helps control the joint damage often caused by this bleeding disorder.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sobi Investigational Site
Milan, Italy
-
Sobi Investigational Site
Naples, Italy
-
Sobi Investigational Site
Rozzano, Italy
-
Sobi Investigational Site
Oslo, Norway
-
Sobi Investigational Site
Barcelona, Spain
-
Sobi Investigational Site
Madrid, Spain
-
Sobi Investigational Site
Seville, Spain
-
Sobi Investigational Site
Valencia, Spain
-
Sobi Investigational Site
Gothenburg, Sweden
-
Sobi Investigational Site
Malmo, Sweden
Conditions
Explore the condition pages connected to this study.